Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India

Abstract

Inflammatory bowel disease patients are at risk of hepatitis B infection. Data on this prevalence from South Asia are limited. We conducted a prospective study comprising of 76 inflammatory bowel disease patients between October 2013 and August 2014. Prevalence of hepatitis B surface antigen in inflammatory bowel disease, ulcerative colitis and Crohn’s disease patients were 2.6%, 2.4% and 3% respectively and that of markers of hepatitis B exposure (hepatitis B surface antigen /hepatitis B core antibody) were 11.8%, 14.3% and 9.1% respectively. Risk factors found significantly more common in those positive for viral markers compared to those negative were age, non-inflammatory bowel disease related surgery and hospital admission. Only 7(9.2%) had completed hepatitis B vaccination. There is a need to create awareness among physicians regarding the importance of hepatitis B screening and vaccination in inflammatory bowel disease patients.

Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis

“…Table 1 shows the characteristics of the included studies. Among these, 17 studies were prospective [18][19][20][21][22][23][24][25]30,31,34,39,45,[48][49][50][51] and 17 were retrospective in nature. [26][27][28][29]32,33,[35][36][37][38][40][41][42][43][44]46,47 The majority of the studies were from Europe 18,20,[24][25][26][27]31,34,36,39,40,47,49 and Asia.…”

“…[26][27][28][29]32,33,[35][36][37][38][40][41][42][43][44]46,47 The majority of the studies were from Europe 18,20,[24][25][26][27]31,34,36,39,40,47,49 and Asia. 28,30,33,35,37,38,41,42,45,46,51 The number of patients in the studies varied from 74 to 5,096 with a mean age from 32.9 to 50.8 years. Majority of the studies included consecutive patients with IBD while 7 studies 20,29,31,34,36,40,44 analyzed data of patients being planned for biologicals.…”

“…A total of 30 studies [19][20][21][44][45][46][47][48][49][50][51] with 17,022 patients reported on HBsAg positivity in patients with IBD. The pooled prevalence of HBsAg was 3.3% (95% confidence interval [CI], 2.5-4.0; I 2 = 91.6%) with significant heterogeneity among the studies (Fig.…”

“…The presence of detectable HBV DNA was reported in 15 studies with 10,663 patients. 21,[24][25][26]28,[31][32][33][34]38,40,41,43,50,51 The pooled prevalence of detectable HBV DNA in patients with IBD and IBD with HBsAg positive cases were 1.0% (95% CI, 0.6-1.4; I 2 = 75.0%) and 61.0% (95% CI, 42.1-79.9; I 2 = 91.6%), respectively (Supplementary Fig. 6).…”

“…The prevalence of anti-HBc (with or without HBsAg) in patients with IBD was reported in 25 studies with 12,265 patien ts. [19][20][21][23][24][25]27,[29][30][31][32][33][34]37,[39][40][41][43][44][45][47][48][49][50][51] The pooled anti-HBc positivity in IBD patients was 14.2% (95% CI, 10.6-17.8; I 2 = 98.2%), with significant heterogeneity among the studies (Supplementary Fig. 7).…”